Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
READY-4: Safety of RelabotulinumtoxinA for Glabellar and Lateral Canthal Lines
NCT04225260Phase 3Completed
- Sponsor
- Galderma
- Start
- Jan 2020
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of relabotulinumtoxinA in glabellar lines, lateral canthal rhytides, sponsored by Galderma. Started Jan 2020; status: completed.
02
Drugs
relabotulinumtoxinA
03
Conditions
glabellar lineslateral canthal rhytides
Beyond the preview
Go deeper on NCT04225260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225260.